The present invention relates to an ophthalmic treatment apparatus and to a beam control method therefor. The ophthalmic treatment apparatus according to the present invention comprises: a beam generating unit for generating beams having different pulse energies; a bubble sensing unit for sensing whether or not bubbles have been generated, as well as the amount of generated bubbles, on the basis of the pulse energy of the beam generated by the beam generating unit and radiated onto the treatment region of an eyeball; and a control unit for controlling the operation of the beam generating unit such that the pulse energy of the beam generated by the beam generating unit can be adjusted in accordance with the signal from the bubble sensing unit.

A device and a method for irradiating the cornea of an eye, wherein the device includes at least the following elements: a ring body, which has a bearing surface embodied concentrically about the longitudinal axis of the device for the purpose of fastening the device on the eye, an irradiation channel for irradiating the cornea, which is located inside the ring body, a light source, which, in the operationally-ready state of the device, is attached inside the ring body for emitting light in the irradiation channel, wherein the bearing surface for fastening the device is arranged outside the irradiation channel, which has the result that the irradiated area itself is not additionally loaded by bearing surfaces of the device.

Formulations, are used for eye treatments, e.g., cross-linking treatments. For example, a therapeutic formulation includes a photosensitizer and delivery agent(s), wherein the delivery agent(s) include at least one of: anesthetic agent(s), analgesic agent(s), tonicity agent(s), or shear-thinning, or viscosity-increasing agent(s). In another example, a method includes applying preparatory formulation(s) to increase a permeability of a corneal epithelium, and applying therapeutic formulation(s) to the epithelium, where the preparatory formulation(s) include zinc metalloproteinase, copper metalloproteinase, papain, bromelain, actinidin, ficain, N-acetylcysteine, ambroxol, carbocisteine, and/or erdosteine. In yet another example, a method includes applying therapeutic formulation(s) to a corneal epithelium to deliver the therapeutic formulation(s) to a stroma, and applying enhancement formulation(s) to the epithelium in response to applying the therapeutic formulation(s), where: the enhancement formulation(s) remove the therapeutic formulation(s) from the epithelium; close tight junctions of the epithelium; promote oxidation for the therapeutic agent(s); and/or further deliver the therapeutic formulation(s) to the stroma.

Provided herein are ophthalmic phototherapy devices and associated phototherapy methods for promoting healing of damaged or diseased eye tissue. An ophthalmic phototherapy device includes a light emitting mechanism for transmitting light of at least one preselected wavelength to the eye tissue. An ophthalmic phototherapy method includes directing light of at least one wavelength for a selected period of time to a portion of damaged or diseased eye tissue, whereby the light transmitted to the damaged or diseased eye tissue stimulates cellular activity in the eye tissue to promote healing.

Devices and approaches for activating cross-linking within corneal tissue to stabilize and strengthen the corneal tissue following an eye therapy treatment. A feedback system is provided to acquire measurements and pass feedback information to a controller. The feedback system may include an interferometer system, a corneal polarimetry system, or other configurations for monitoring cross-linking activity within the cornea. The controller is adapted to analyze the feedback information and adjust treatment to the eye based on the information. Aspects of the feedback system may also be used to monitor and diagnose features of the eye. Methods of activating cross-linking according to information provided by a feedback system in order to improve accuracy and safety of a cross-linking therapy are also provided.

The present invention relates to a medicinal material for light therapy, comprising a matrix material and a photosensitizer, wherein the photosensitizer is dispersed inside the matrix material by copolymerization, is mixed inside the matrix material, or attached to the surface of the matrix material by surface grafting, modification, coating and the like. The present material can kill diseased tissue cells with a radiation under selected wavelength so as to obtain a phototherapy treatment of ophthalmic diseases. The present invention also provides a process for preparing the material and a use in preparing an ophthalmic medical device.

An ophthalmic treatment system of an embodiment is used for performing therapy on target tissue in a patient's eye. The ophthalmic treatment system comprises, a light source, a delivery system, an obtaining means, a setting means and control electronics. The light source is configured to produce treatment light. The delivery system is configured to deliver the treatment light to the patient's eye. The obtaining means is configured to obtain information acquired by capturing the patient's eye. The setting means is used for setting a position in the patient's eye by using the information obtained by the obtaining means. The control electronics is configured to control the delivery system based on the position set by the setting means.

The invention provides a method of noninvasively treating a condition associated with reduced integrity or increased permeability of an epithelial layer by a series of magnetic pulses having a magnitude of up to 3 T, wherein the magnetic pulses are designed to induce an electric field having a magnitude of up to 250 Volt per meter adjacent to a target treatment area, the condition particularly being ocular condition associated with reduced barrier function of the cornea. The invention provides a device for effecting the tissue treatment, creating series of pulses exhibiting a rate of change of more than 200 T/s in the absolute value.

In a corneal measurement system, an optical element focuses an excitation light to an area of corneal tissue at a selected depth. In response, a fluorescing agent applied to the cornea generates a fluorescence emission. An aperture of a pinhole structure selectively transmits the fluorescence emission from the area of corneal tissue at the selected depth. A detector captures the selected fluorescence emission transmitted by the aperture and communicates information relating to a measurement of the selected fluorescence emission captured by the detector. A controller receives the information from the detector and determines a measurement of the fluorescing agent in the area of corneal tissue at the selected depth. The system may include a scan mechanism that causes the optical element to scan the cornea at a plurality of depths, and the controller may determine a measurement of the fluorescing agent in the cornea as a function of depth.

A system for treatment of corneal tissue includes one or more light sources that generate excitation light delivered to corneal tissue treated with a cross-linking agent. The excitation light causes the cross-linking agent to fluoresce by emitting an emission light at a plurality of emission wavelengths. The system includes an image capture system that captures image(s) of the corneal tissue. The image(s) indicate at least two of the emission wavelengths. The system includes a controller that receives the image(s). The controller: identifies each of the at least two emission wavelengths in the image(s); determines, from the image(s), respective characteristics associated separately with each of the at least two emission wavelengths; and provides information relating to cross-linking activity generated by the cross-linking agent in the corneal tissue based on the respective characteristics associated with each of the at least two emission wavelengths.